Charles Explorer logo
🇬🇧

Alirocumab, Praluent: Clinical studies: An overwiev

Publication at First Faculty of Medicine |
2016

Abstract

Alirocumab, Praluent represents the new lipid lowerin drug from the group of PCSK9 inhibitors. The artickle provides an overwiev of clinical studies up to date